Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neuronavigation-assisted Stereotactic Minimally Invasive Puncture Combined With Tenecteplase for the Treatment of Acute Spontaneous Deep Intracerebral Hemorrhage(NAS-TNK)： a Randomized, Outcome-blinded, Multi-center Trial

NCT06868511 is registered in ClinicalTrials.gov with Beijing Tiantan Hospital as lead sponsor.

NCT NCT06868511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06868511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neuronavigation-assisted Stereotactic Minimally Invasive Puncture Combined With Tenecteplase for the Treatment of Acute Spontaneous Deep Intracerebral Hemorrhage(NAS-TNK)： a Randomized, Outcome-blinded, Multi-center Trial
Lead sponsor
Beijing Tiantan Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
April 25, 2025
Completion date
September 1, 2027
Enrollment
732 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

deep intracerebral hemorrhage (ich)